ArticleJournal of Ayurveda and integrative medicine2026
Deciphering the action mechanism of the sacred plant "Ashvattha" (Ficus religiosa L.) in the treatment of delayed-onset muscle soreness.
Article in Journal of Ayurveda and integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDOMS is a common post-exercise syndrome characterized by pain, stiffness, and decreased muscle function. Conventional therapies have limited efficacy and have potential side effects.
objectiveThis study explored the molecular mechanisms of Ficus religiosa's alleviation of DOMS using network pharmacology, molecular docking, and molecular dynamics simulation analyses. MATERIALS AND
methodsThis study used a network pharmacology framework to identify and analyze the phytochemicals from F. religiosa. Databases like IMPPAT 2.0 were used to retrieve potential compounds, while SwissTargetPrediction predicted target proteins. Therapeutic targets were identified using Genecards and OMIM databases. Protein-protein interaction networks were analyzed using STRING and Cytoscape software, while pathway enrichment was conducted using Enrichr. Molecular docking was performed using AutoDockTools (v1.5.7), followed by molecular dynamics simulations using GROMACS to validate target-compound interactions.
resultsOf the 140 phytochemicals, 44 met the drug-likeness and bioavailability criteria and were associated with 39 potential therapeutic targets for DOMS. KEGG enrichment analysis revealed inflammation, oxidative stress, and immune regulation as the primary mechanisms of action. Prostaglandin-endoperoxide synthase 2 (PTGS2) was identified as a critical target. Molecular docking showed that compounds such as α-eudesmol, epi-γ-eudesmol, and α-cadinol exhibited superior binding affinities for PTGS2 compared to ibuprofen. Finally, molecular dynamics simulation demonstrated that α-cadinol exhibited the most stable binding owing to its robust hydrogen bonding, whereas epi-α-cadinol displayed progressive stabilization and efficient accommodation inside the active region of the protein.
conclusionThis study suggests that F. religiosa could be used as a therapeutic agent for the management of DOMS. The key compounds, α-cadinol and epi-α-cadinol, show potential anti-inflammatory and analgesic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.